Navigation Links
Lawson research team working to personalize cancer care
Date:12/12/2011

LONDON, ON - The Lawson Translational Cancer Research Team (LTCRT) of the Lawson Health Research Institute is one of five groups participating in a new study that seeks to personalize cancer drug treatment.

The Genomics Pathway Sequencing (GPS) study, led by the Princess Margaret Hospital in Toronto, will assess the feasibility of identifying specific genetic markers (mutations) in the DNA of patients' tumours. This information will then be used to identify more targeted treatments.

The Lawson team has developed a process for London where they can obtain a fresh tissue sample from the patient's tumour biopsy. This tissue is sent away to a lab in Toronto where two types of DNA analysis are performed. Within three weeks a report on the cancer's genetic profile is provided to the patient's oncologist. "With this new information, it is hoped the oncologist can deliver a more tailored treatment plan," says Dr. Eric Winquist, lead of the LTCRT and medical oncologist at the London Health Sciences Centre.

Jennifer Malone from London, Ontario was diagnosed with cancer in 2006. Over the next five years, she exhausted all standard cancer treatments. A DNA analysis of her tissue sample identified a mutation in a gene known as KRAS. Fortunately, a study investigating a new drug known to target mutations in KRAS was available at the Princess Margaret Hospital and Jennifer was enrolled.

Since starting the experimental treatment, Jennifer's tumour has regressed and many of her cancer symptoms have improved or disappeared. It is "remarkable and amazing," says Jennifer. "Participating in this study gave me an option where previously no option existed."

While the GPS study is still in early development, the idea of more precisely matching patient treatment to their cancer's individual genetic characteristics holds great promise. "We are excited to be discovering what the future holds for our patients using a personalized approach to cancer treatment," says Dr. Winquist, "and the GPS study is a promising look at what this future may look like."


'/>"/>

Contact: Julia Capaldi
julia.capaldi@lhsc.on.ca
519-685-8500 x75616
Lawson Health Research Institute
Source:Eurekalert

Related biology news :

1. Professor Dr. Alexander (Sandy) Lawson is awarded the 2011 Herman Skolnik Award
2. Lawson researchers take control of cancer
3. Lawson researchers share in $2.2 million grant
4. Lawson research shows Canadians dont believe their eyes
5. Wistar Institute researcher receives New Innovator award from NIH
6. NC State researchers get to root of parasite genome
7. White Mountain Research Station to host climate change conference
8. Stevens awarded $1M for advanced biofuels research
9. Researchers find animal with ability to survive climate change
10. Researchers find an essential gene for forming ears of corn
11. Researchers note differences between people and animals on calorie restriction
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/12/2017)... research undertaken by Fit Small Business has revealed ... simply asked which office technology had they not used in ... Insights on what will be key features in ... industry leaders including Penelope Trunk , Martin Lindstrom ... Some of these findings included; ...
(Date:1/6/2017)... JOLLA, Calif. , Jan. 6, 2017 /PRNewswire/ ... 1 safety studies in healthy volunteers of a ... intended to treat acute pancreatitis. ... is typically a mild disorder, but can be ... organ failure and sepsis, where extended hospital stays, ...
(Date:1/4/2017)... , Jan. 4, 2017  CES 2017 – ... sensor technology, today announced the launch of two ... systems, the highly-accurate biometric sensor modules that incorporate ... technology, experience and expertise. The two new designs ... specifically for hearables, and Benchmark BW2.0, a 2-LED ...
Breaking Biology News(10 mins):
(Date:1/21/2017)... -- Aratana Therapeutics, Inc. (NASDAQ: PETX ), ... and commercialization of innovative biopharmaceutical products for companion animals, ... North America 2016. ... the FDA approval of three innovative therapeutics in 2016, ... oral solution) and NOCITA ® (bupivacaine liposome injectable ...
(Date:1/20/2017)... http://www.Financialbuzz.com - According ... causes of death worldwide. There were 8.2 million cancer ... related deaths increased gradually over time, the death rates ... various cancers continues to drive demand of biological therapies ... Market Insights, Inc. cancer biological therapy market size was USD ...
(Date:1/19/2017)... 19, 2017 /PRNewswire -- WuXi AppTec, a leading ... and technology platform, today announced that it has ... preclinical drug discovery contract research organization (CRO). After ... wholly-owned subsidiary of WuXi, and will continue to ... greater services. The acquisition will further strengthen WuXi,s ...
(Date:1/19/2017)... , Jan. 19, 2017  ArmaGen, Inc., ... Schmidt , Ph.D., as chief executive officer, as ... directors. Dr. Schmidt brings to ArmaGen more than 17 ... research and development of biotherapeutics and pharmaceuticals. ... with the diverse experience and skillset necessary to ...
Breaking Biology Technology: